Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Authors
Martin, MHolmes,
Ejlertsen, B
Delaloge, S
Moy, B
Iwata, H
von Minckwitz, G
Chia, S
Mansi, J
Barrios, C
Gnant, M
Tomašević, Z
Denduluri, N
Šeparović, R
Gokmen, E
Bashford, A
Ruiz Borrego, M
Kim, S
Jakobsen, E
Ciceniene, A
Inoue, K
Overkamp, F
Heijns, J
Armstrong, Anne C
Link, J
Joy, A
Bryce, R
Wong, A
Moran, S
Yao, B
Xu, F
Auerbach, A
Buyse, M
Chan, A
Affiliation
Instituto de Investigacion Sanitaria Gregorio Maranon, Grupo Espanol de Investigacion en Cancer de Mama (GEICAM), Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Universidad Complutense, Madrid, SpainIssue Date
2017-12
Metadata
Show full item recordAbstract
ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-based adjuvant therapy in women with HER2-positive breast cancer. We report updated efficacy outcomes from a protocol-defined 5-year follow-up sensitivity analysis and long-term toxicity findings.Citation
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. 2017, 18(12): 1688-1700 Lancet OncolJournal
The Lancet OncologyDOI
10.1016/S1470-2045(17)30717-9PubMed ID
29146401Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(17)30717-9